You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Pathologic complete response (pCR)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to

Active, not recruiting
  • Esophageal Cancer
  • follow up
  • Guangzhou, Guangdong, China
    Jianhua Fu
Sep 24, 2023

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial

Not yet recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +3 more
  • Pembrolizumab
  • +5 more
  • (no location specified)
Apr 12, 2023

Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8

Active, not recruiting
  • Anatomic Stage IIB Breast Cancer AJCC v8
  • +19 more
  • Gilbert, Arizona
  • +4 more
Dec 6, 2022

pCR After Neoadjuvant Therapy in Breast Cancer Patients

Recruiting
  • Breast Cancer
  • TIL assessment in pre-existing histopathological specimens
  • Cairo, Egypt
    Faculty of Medicine, Ain Shams University
Jul 25, 2022

Breast Cancer Invasive Trial (Breast surgery omission)

Not yet recruiting
  • Breast Cancer Invasive
  • Breast surgery omission
  • (no location specified)
Aug 16, 2022

Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III Trial in Madrid (neoadjuvant treatment)

Completed
  • Rectal Cancer, Adenocarcinoma
  • +4 more
  • neoadjuvant treatment
  • Madrid, Spain
    Hospital La Princesa
Aug 8, 2022

t Pathologic Complete Response Observed in HER2 Positive Breast

Completed
  • HER2+ Breast Cancer
  • Rawalpindi, Punjab, Pakistan
    Rawalpindi Medical University
Jun 26, 2023

Predictive Factor of Pathologic Complete Response After

Completed
  • Rectum Cancer
    • Bangkok, Bankok, Thailand
      Chairat Supsamutchai
    May 15, 2022

    HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)

    Active, not recruiting
    • HER2-positive Breast Cancer
    • PIK3CA analysis
    • Rome, RM, Italy
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Feb 20, 2023

    Axillary Lymph Node Dissection, Pathological Complete Response, Neoadjuvant Systemic Therapy Trial in Nanjing (Stained region

    Recruiting
    • Axillary Lymph Node Dissection
    • +4 more
    • Stained region Lymph Node Biopsy (SrLNB)
    • Regional lymph node radiotherapy (RNI) including the axilla
    • Nanjing, China
      The First Affiliated Hospital of Nanjing Medical University
    Jul 10, 2023

    MRI Based AI System to Predict pCR for Rectal Cancer

    Recruiting
    • Rectal Cancer
    • artificial intelligence prediction system
    • the radiologists
    • Guangzhou, Guangdong, China
    • +2 more
    Feb 19, 2021

    Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response

    Recruiting
    • Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB
    • Vacuum-assisted biopsy
    • Saint-Petersburg, Russian Federation
      Petr Krivorotko
    Jun 14, 2022

    Breast Cancer Trial (Omission of radiotherapy)

    Not yet recruiting
    • Breast Cancer
    • Omission of radiotherapy
    • (no location specified)
    Jun 8, 2022

    Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer Trial in Winston-Salem (drug, dietary supplement,

    Recruiting
    • Triple Negative Breast Cancer
    • +2 more
    • Standard of Care Neoadjuvant Chemotherapy
    • +2 more
    • Winston-Salem, North Carolina
      Wake Forest Baptist Health Sciences
    Feb 8, 2022

    Head and Neck Squamous Cell Carcinoma Trial in Zhuhai (dose-reduced radiotherapy)

    Recruiting
    • Head and Neck Squamous Cell Carcinoma
    • dose-reduced radiotherapy
    • Zhuhai, Guangdong, China
      Fifth Affiliated Hospital of Sun Yat-sen University
    May 3, 2023

    Radiation OmisSion in PAtients With CLinically Node Negative

    Not yet recruiting
    • Breast Cancer
      • (no location specified)
      May 10, 2023

      Assessment Model of PCR After NAT on Breast Cancer AI Technology

      Recruiting
      • Breast Cancer
      • Neoadjuvant therapy
      • Beijing, Beijing, China
        National Cancer Center/National Clinical Research Center for Can
      Jun 30, 2022

      After Neoadjuvant Chemotherapy for Breast Cancer

      Recruiting
      • TN ER-/PR-/HER2- Breast Cancer
      • +3 more
      • Standard Trimodality Breast Imaging
      • Minneapolis, Minnesota
        University of Minnesota Masonic Cancer Center
      Aug 13, 2021

      Breast Cancer Trial in United States (MRI Biopsy)

      Recruiting
      • Breast Cancer
      • MRI Biopsy
      • Basking Ridge, New Jersey
      • +6 more
      Nov 23, 2022

      Breast Cancer, HER2-positive Breast Cancer Trial in Los Angeles (Omit breast radiation)

      Not yet recruiting
      • Breast Cancer
      • HER2-positive Breast Cancer
      • Omit breast radiation
      • Los Angeles, California
        Cedars-Sinai Medical Center
      May 10, 2022

      Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma Trial in United States

      Not yet recruiting
      • Esophageal Adenocarcinoma
      • +2 more
      • Palo Alto, California
      • +5 more
      Jan 12, 2023

      Breast Tumor Trial in Seoul (Minimally-invasive biopsy, wide excision)

      Completed
      Has Results
      • Breast Neoplasm
      • Minimally-invasive biopsy
      • wide excision
      • Seoul, Korea, Republic of
        Seoul National University Hospital
      Mar 27, 2020

      ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer

      Not yet recruiting
      • Rectal Cancer
      • Non Metastatic Rectal Cancer
      • ctDNA
      • Boston, Massachusetts
      • +1 more
      Nov 17, 2022

      Esophagus Adenocarcinoma, Esophagus Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Dallas

      Recruiting
      • Esophagus Adenocarcinoma
      • +2 more
      • Dallas, Texas
        Dallas VA Medical Center
      Nov 2, 2021

      Urothelial Bladder Carcinoma Trial in Spain (Sacituzumab govitecan, Zimberelimab, Domvanalimab)

      Not yet recruiting
      • Urothelial Bladder Carcinoma
      • Sacituzumab govitecan
      • +2 more
      • Santiago De Compostela, A Coruña, Spain
      • +9 more
      Nov 14, 2023